Search results: Sage Journals

Restricted accessCase reportFirst published February, 2025

Ofatumumab-associated colitis: A case report

Ashish D Patel, Alexa Connors, Megan E Esch

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published March, 2025

Ofatumumab-exposed breastfeeding in multiple sclerosis patients

Laura Witt

Multiple Sclerosis Journal

Open accessCase reportFirst published 2025

Ofatumumab in pediatric multiple sclerosis: a case series

Wenlin Wu, Yanping Ran, Chi Hou [...]

Therapeutic Advances in Neurological Disorders

Free accessResearch articleFirst published August, 2012

Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia

Martin J.S. Dyer

Therapeutic Advances in Hematology

Open accessReview articleFirst published 2011

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia

Chadi Nabhan, Neil E. Kay

Clinical Medicine Insights: Oncology

Restricted accessResearch articleFirst published July, 2022

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study

Jun-ichi Kira, Jin Nakahara, Denis V Sazonov [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published October, 2011

Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia

Ginah Nightingale

Annals of Pharmacotherapy

Restricted accessCase reportFirst published February, 2026

Tumefactive demyelinating lesion during B-cell depletion therapy by ofatumumab

Koji Shinoda, Katsuhisa Masaki, Ayano Matsuyoshi [...]

Multiple Sclerosis Journal

Open accessCase reportFirst published 2026

Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies

Dalia L Rotstein, Sheliza Halani, Peter Vadas [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published October, 2023

Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension

Stephen L Hauser, Ronald Zielman, Ayan Das Gupta [...]

Multiple Sclerosis Journal

Restricted accessCase reportFirst published February, 2025

Ofatumumab-associated colitis: A case report

Ashish D Patel, Alexa Connors, Megan E Esch

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published March, 2025

Ofatumumab-exposed breastfeeding in multiple sclerosis patients

Laura Witt

Multiple Sclerosis Journal

Open accessCase reportFirst published 2025

Ofatumumab in pediatric multiple sclerosis: a case series

Wenlin Wu, Yanping Ran, Chi Hou [...]

Therapeutic Advances in Neurological Disorders

Free accessResearch articleFirst published August, 2012

Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia

Martin J.S. Dyer

Therapeutic Advances in Hematology

Open accessReview articleFirst published 2011

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia

Chadi Nabhan, Neil E. Kay

Clinical Medicine Insights: Oncology

Restricted accessResearch articleFirst published July, 2022

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study

Jun-ichi Kira, Jin Nakahara, Denis V Sazonov [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published October, 2011

Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia

Ginah Nightingale

Annals of Pharmacotherapy

Restricted accessCase reportFirst published February, 2026

Tumefactive demyelinating lesion during B-cell depletion therapy by ofatumumab

Koji Shinoda, Katsuhisa Masaki, Ayano Matsuyoshi [...]

Multiple Sclerosis Journal

Open accessCase reportFirst published 2026

Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies

Dalia L Rotstein, Sheliza Halani, Peter Vadas [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published October, 2023

Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension

Stephen L Hauser, Ronald Zielman, Ayan Das Gupta [...]

Multiple Sclerosis Journal